Therapy: Spleen tyrosine kinase inhibitors--novel therapies for RA?
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 21304505.
- Also identified by DOI 10.1038/nrrheum.2011.8.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In patients with active rheumatoid arthritis despite therapy with DMARDS, treatment with a spleen tyrosine kinase inhibitor has achieved similar response rates to those achieved in clinical trials of other drugs, including biologic agents. Where might these agents fit in the current armamentarium against this disease?
Medical subject headings
- Arthritis, Rheumatoid
- Enzyme Inhibitors
- Intracellular Signaling Peptides and Proteins
- Protein-Tyrosine Kinases